From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q2 2018 call → NOWe need answer YES or NO. Need analyze transcript. Question: Does management describe that company has recently crossed from candidate to approved/specified/listed/qualified/registered/reimbursed/pre-authorized inside buyers' systems so future business can arrive without discrete selling event, and that status is new enough most volume still ahead? Need use only transcript. Look for mentions of formulary, reimbursement, listing, etc. Transcript discusses Calcimimetics moving from Part D to Part B, pharmacy to clinics. This is about reimbursement pathway? They are moving from Part D to Part B, pharmacy to clinics. This could be about being included in payment pathway. But is it "recently crossed" and "most volume ahead"? Let's examine. Rice: "Calcimimetics; they continue to evolve. As you remember, we're moving from Part D in David to Part B in Barry. Pharmacy to the clinics. We believe that we're probably two quarters in to two to four quarter process in order to get this sorted out with great clarity in detail. Let's keep in mind that this is a medical decision, it's an algorithm based on focusing to the highest outcomes for our patients and this is a titration, our step up situation where we start with low doses and move up overtime in a very safe and effective way as determined by our patients physicians." This is about calcimimetics (drug) moving from Part D to Part B? Actually Part D is prescription drug coverage, Part B is medical insurance. For dialysis patients, oral calcimimetics under Part D, but if administered in clinic? They are moving from Part D to Part B? This might be about reimbursement pathway. But is it "company has crossed into approved/specified/listed"? Not exactly. It's about drug reimbursement classification. They are in process, two quarters into two to four quarter process. Not yet fully sorted. Also not about company being placed into buyer's system. It's about drug payment pathway. Also "most volume still ahead" maybe yes because process ongoing. But question asks "company has recently crossed from being a candidate that buyers must be persuaded to consider into being an APPROVED, SPECIFIED, LISTED, QUALIFIED, REGISTERED, REIMBURSED, OR PRE-AUTHORIZED choice inside buyers' own purchasing, reimbursement, formulary, specification, procurement, network, catalog, or program systems".
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.